Product category:
Antibodies
News Release from: Oxford BioMedica
Edited by the Laboratorytalk Editorial
Team on 02 August 2006
MoNuDin in the treatment of motor neuron
disease
Oxford BioMedica presented 'promising' preclinical data from its motor neuron disease programme at two major international conferences in November 2003
Nick Mazarakis and Mimoun Azzouz, from the company's neurobiology group, presented data showing that the MoNuDin programme has achieved a major technical milestone In an industry standard animal model of motor neuron disease, treatment with MoNuDin resulted in significant motor (movement) improvement, a substantial delay in the onset of disease and increased survival time
This article was originally published on Laboratorytalk on 25 Jun 2003 at 8.00am (UK)
Related stories
Manufacturing process for Parkinson's drug
First discussion of the novel production approach used for ProSavin, a LentiVector-based product, to be made at Bio 2003 this week in Washington DC.
Avian transgenic breakthrough reported
Results are first proof-of-principle with an avian-expressed version of interferon beta; it is expected that the Ova system will be capable of cost-effectively expressing many therapeutic proteins
MoNuDin comprises a neuroprotective gene delivered by the Company's proprietary LentiVector system.
The product is designed to be injected into muscle, but mediates its therapeutic effect within the nerve cells of the spine.
There is currently no known cure for motor neuron disease, a condition that affects approximately 100,000 people in Europe and the US.
Oxford BioMedica's novel programme is supported by the largest US charitable organisation for this condition, the Amyotrophic Lateral Sclerosis (ALS) Association.
The ground breaking technology employed in MoNuDin is also used in the company's spinal muscular atrophy (SMA) programme.
The Company estimates that, if successful, these two products could reach markets in excess of $300 million per annum.
Commenting on the presentations, Oxford BioMedica's chief executive, Prof Alan Kingsman said: "The company's neurobiology programme goes from strength to strength.
"These new data pave the way for MoNuDin to enter clinical development on schedule and, in addition, they bode well for the SMA programme".
• Oxford BioMedica: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
